article thumbnail

LimFlow Limits Limb-Threatening Ischemia

CardiacWire

Late-breaking second year results from the PROMISE II trial showed that the LimFlow system achieved strong outcomes for avoiding amputations and promoting limb salvage among “no-option” patients with chronic limb-threatening ischemia (CLTI). Ischemia in the treated limb also decreased significantly, with 65.8%

article thumbnail

Revascularization Strategies in Stable Coronary Artery Disease: ISCHEMIA Trial Insights

Cardiology Update

In the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial, researchers examined the risk of ischemic events in patients with stable coronary artery disease. years, with 57.1% occurring within 30 days after CABG. years, with 21.1% occurring within 30 days after PCI. years, with 6.3%

article thumbnail

Esperion Presents New Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL

DAIC

18, 2024 — In November, Esperion presented an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. tim.hodson Tue, 12/03/2024 - 16:52 Nov. These data were presented at the 2024 American Heart Association Scientific Sessions, in Chicago, IL.

article thumbnail

Improving Life Quality in Chronic Limb-Threatening Ischemia Through Revascularization

DAIC

milla1cf Thu, 05/16/2024 - 15:35 May 16, 2024 — A recent publication in the American Heart Association Circulation highlights a comprehensive investigation to assess the impact of revascularization strategies on the health-related quality of life (HRQoL) of patients suffering from chronic limb-threatening ischemia. years, respectively.

Ischemia 111
article thumbnail

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. Getty Images milla1cf Thu, 05/02/2024 - 10:12 May 2, 2024 — BioCardia, Inc. ,

article thumbnail

Examination of Inter‐α Inhibitor Proteins in Permanent and Transient Focal Ischemia

Journal of the American Heart Association

More recently, IIP improved focal ischemic stroke outcomes in mouse models. Inter inhibitor proteins (IIPs) are a family of structurally related glycoproteins with 2 major forms (inter inhibitor and pre inhibitor) in blood. Purified human plasmaderived IIP has beneficial effects in sepsis and hypoxicischemic brain injury.

article thumbnail

Does Use of Drug-Coated Devices Improve Outcomes in Chronic Limb-Threatening Ischemia?

NEJM Journal Watch - Cardiology

No, according to a randomized trial in the U.K.